Microscopic polyangiitis classification: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Microscopic polyangiitis}}
{{Microscopic polyangiitis}}
{{CMG}} {{AE}}{{VKG}}
{{CMG}}; {{AE}} {{VKG}}


==Overview==
==Overview==

Revision as of 16:33, 7 June 2018

Microscopic polyangiitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Microscopic polyangiitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Radiation therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Microscopic polyangiitis classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Microscopic polyangiitis classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Microscopic polyangiitis classification

CDC on Microscopic polyangiitis classification

Microscopic polyangiitis classification in the news

Blogs on Microscopic polyangiitis classification

Directions to Hospitals Treating Type chapter name here

Risk calculators and risk factors for Microscopic polyangiitis classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]

Overview

According to The International Chapel Hill Consensus Conference (CHCC) criteria based on antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides (AAV) into granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), including renal-limited vasculitis (RLV), and eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss).

Classification

References

  1. Rao JK, Allen NB, Pincus T (September 1998). "Limitations of the 1990 American College of Rheumatology classification criteria in the diagnosis of vasculitis". Ann. Intern. Med. 129 (5): 345–52. PMID 9735061.
  2. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC, Hoffman GS, Hunder GG, Kallenberg CG (February 1994). "Nomenclature of systemic vasculitides. Proposal of an international consensus conference". Arthritis Rheum. 37 (2): 187–92. PMID 8129773.
  3. Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, Calabrese LH, Fries JF, Lie JT, Lightfoot RW (August 1990). "The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis". Arthritis Rheum. 33 (8): 1101–7. PMID 2202308.
  4. Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, Mahr A, Segelmark M, Cohen-Tervaert JW, Scott D (February 2007). "Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies". Ann. Rheum. Dis. 66 (2): 222–7. doi:10.1136/ard.2006.054593. PMC 1798520. PMID 16901958.

Template:WH Template:WS